Novo Nordisk's Ozempic outperforms Eli Lilly's Trulicity, shares see biggest jump in a month
```
In a highly anticipated drug showdown, Novo Nordisk achieved a crucial victory.
A study involving nearly 60,000 diabetes and heart disease patients using Medicare data showed that patients taking Ozempic had a 23% lower risk of heart attack, stroke, or death compared to those using Trulicity. Novo Nordisk announced